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Abstract  
Background: The progress in material science and the recent advances in 
biodegradable/biocompatible polymers and magnetic iron oxide nanoparticles have led to develop 
innovative diagnostic and therapeutic strategies for diseases based on multifunctional nanoparticles, 
which include contrast medium for magnetic resonance imaging, agent for hyperthermia and 
nanocarriers for targeted drug delivery. The aim of this work is to synthesize and characterize 
superparamagnetic iron oxide (magnetite), and to encapsulate them into poly (3-hydroxybutyrate-co-3-
hydroxyvalerate) (PHBV) nanoparticles for biomedical applications.  
Results: The magnetite nanoparticles were confirmed by X-ray diffraction and exhibited a size of 22.3 
± 8.8 nm measured by transmission electron microscopy (TEM). Polymeric PHBV nanoparticles loaded 
with magnetite (MgNPs) were analyzed using dynamic light scattering and showed a size of 258.6 ± 
35.7 nm and a negative zeta potential (-10.8 ± 3.5 mV). The TEM examination of MgNPs exhibited a 
spherical core-shell structure and the magnetic measurements showed in both, non-encapsulated 
magnetite and MgNPs, a superparamagnetic performance. Finally, the in vitro studies about the 
magnetic retention of MgNPs in a segment of small intestine of rats showed an active accumulation in 
the region of the magnetic field.  
Conclusions: The results obtained make the MgNPs suitable as potential magnetic resonance 
imaging contrast agents, also promoting hyperthermia and even as potential nanocarriers for site-
specific transport and delivery of drugs. 
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INTRODUCTION 
Magnetic nanoparticles provide a multifunctional platform for scientific and clinical applications, such as 
biosensors, protein and cell separation systems and magnetic carriers for hyperthermia and tissue-
specific drug delivery (Gao et al. 2009). Iron oxide nanoparticles are highly biocompatible in the body 
because the iron uptake, transport and storage in the liver are highly regulated by proteins such as 
ferritin and transferrin (Corchero and Villaverde, 2009). On the other hand, iron oxide nanoparticles are 
cleared efficiently from the body and do not induce oxidative stress or long-term changes in liver 
enzyme levels (Jain et al. 2008). In addition, Fe-based nanoparticles, such as magnetite (Fe3O4) and 
maghemite (γ-Fe2O3), exhibit lower toxicity and less susceptibility to oxidation than other magnetic 
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materials with high magnetic moments, such as cobalt and nickel making them suitable for diagnostic 
and therapeutic strategies (Sanvicens and Marco, 2008).  
The magnetic resonance imaging (MRI) as a non-radiating biomedical imaging technique has shown 
advantages over others strategies used to elucidate the evolution and progression of different 
pathologies, which include brain aneurysms, stroke, and breast, brain, and prostate tumors (Cormode 
et al. 2009). Gadolinium is the most used contrast agent for MRI; however, magnetite nanoparticles 
have recently been extensively tested as contrast agents for MRI because their magnetic susceptibility 
is higher than that of gadolinium chelates, and their magnetic properties alters the relaxation times T2 
of the resonance (Haw et al. 2010). An example of these nanoparticles is GastroMARK
®
, which is a 
commercial MRI contrast agent comprising silicone-coated superparamagnetic iron oxide 
nanoparticles. GastroMARK
®
 allows to obtain images with an enhance delineation of the bowel, which 
makes it distinguished from organs and tissues that are adjacent of the gastrointestinal tract.  
The magnetic characterization of particles is determined by measuring their response to an external 
magnetic field, Ha. If we consider a system composed of several nanoparticles small enough such that 
each is a monodomain with negligible anisotropy, it is possible for the thermal energy, KBT, to become 
higher than or equal to the activation energy. In this case, the particle can orient its magnetization 
along any direction, thereby, losing its magnetic stability (Xu and Sun, 2009). If the direction of the 
magnetization changes several times during a measurement, then the measured magnetization will be 
zero at zero external fields. This effect, known as superparamagnetism, is fundamental to many 
biological applications (Lee et al. 2009). Superparamagnetic particles respond rapidly to an external 
field, which allows the relaxation time to be varied. In nuclear MRI, the images exhibit a resonant 
response to an alternating magnetic field, which can be used to heat up the surrounding tissue by 
energy transfer and generate hyperthermia. Thus, nuclear MRI is a promising tool for cancer therapy 
(Kim et al. 2009).  
The application of magnetic nanoparticles as contrast agents for MRI depends on their properties, such 
as magnetic susceptibility, superparamagnetic performance, and biocompatibility with specific 
biomedical applications. Magnetite nanoparticles are not stable in an environment with abundant 
oxygen, because Fe
2+
 ions are oxidized to iron oxyhydroxides, losing their original magnetic properties.  
The development of biocompatible and biodegradable polymers has provided a robust platform to 
create innovative diagnostic and therapeutic strategies based on micro and nanoparticles (Shi et al. 
2011; Vilos and Velásquez, 2012). The polymeric nanoparticles as drug delivery system have shown 
suitable physical and mechanical properties, which can be easily modified, enabling control of the 
pharmacokinetic and biodistribution of drugs (Tekade and Gattani, 2009). Poly (D, L lactide-co-
glycolide), poly (sebacic anhydride) and poly (ε-caprolactone) are some of the most commonly used 
polymers in biomedicine (Pillai and Panchagnula, 2001). The poly (3-hydroxybutyrate-co-3-
hydroxyvalerate) (PHBV) is a biodegradable and biocompatible polymer that has shown useful 
properties for drug delivery and tissue engineering (Vilos et al. 2012; Vilos et al. 2013). PHBV is cost-
effective and has physicochemical properties similar to those of the most widely used polymers 
(Holmes, 1985). In this study, we synthesized and characterized iron oxide (magnetite), formulated 
magnetite-loaded PHBV nanoparticles, and examined their magnetic properties as putative MRI 
contrast agents for hyperthermia induction and tissue-specific drug delivery. 
MATERIALS AND METHODS  
The aqueous suspension of silicone-coated, superparamagnetic iron oxide (GastroMARK
®
) was 
purchased from AMAG Pharmaceuticals, Inc. (Lexington, MA, USA). An ultrasonic processor, VCX 130 
PB (Sonics Inc.; Newtown, CT, USA) fitted with a microtip Ti-6Al-4V probe was used to synthesize the 
iron oxide-loaded polymeric nanoparticles. PHBV (12 wt.% PHV content) and polyvinyl alcohol (PVA, 
MW 30,000-70,000) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Analytical grade 
dichloromethane (DCM), methanol, and solution ammonia (NH3(aq)), iron (II) chloride tetrahydrate 
(FeCl2 x 4H2O), iron (III) chloride hexahydrate (FeCl3 x 6H2O), and potassium nitrate (KNO3) were 
purchased from Merck (Darmstadt, Germany).  
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Synthesis of magnetite  
The synthesis method used has been widely reported (Nedkova et al. 2006; Frimpong et al. 2010; 
Utkan et al. 2011). Iron oxides (either Fe3O4 or δ -Fe2O3) can be synthesized through the co-
precipitation of Fe
2+
 and Fe
3+
 aqueous salt solutions by addition of a base. The control of size, shape 
and composition of nanoparticles depends on the type of salts used (e.g. chlorides, sulphates, nitrates, 
perchlorates, etc.), Fe
2+
 and Fe
3+
 ratio, pH and ionic strength of the media. We use the co-precipitation 
method described by Gupta and Gupta (2005) and modifications by Gutiérrez et al. (2010) to obtain 
superparamagnetic magnetite nanoparticles. We mixed a FeCl2, and FeCl3 solutions (1 M) in a 1:2 
molar ratio. After these processes we added Na3C3H5O (COO)3 (0.3 M). The final solution was mixed 
during 1 hr at room temperature (298 K) in a N2 atmosphere. The precipitate was washed to eliminate 
salts excess.  
Preparation of magnetite-loaded PHBV nanoparticles  
A modification of the double emulsion water-in-oil-in-water (W1/O1/W2) evaporation method described 
by Gomez-Lopera (2001) was used to develop colloidal magnetite-loaded nanoparticles (MgNPs) 
(Figure 1). Experimentally, a first water-in-oil (W1/O1) emulsion was prepared by the incorporation of 
300 μL of an aqueous solution of magnetite (0.5 mg/mL) in 1 mL of PHBV solution (25 mg/mL) in DCM 
using an ultrasonic processor equipped with a microtip probe for 60 sec at 125 W in an ice bath 
because the microtip produces an exothermal reaction. This emulsion was added to 4 mL of an 
aqueous solution of PVA (1% w/v), and was sonicated for 60 sec at 125 W in an ice bath to obtain the 
second emulsion (W1/O1/W2). The second emulsion was immediately poured into a beaker containing 
20 mL of PVA solution (0.1% w/v), and stirred for 12 hrs to evaporate the DCM. Finally, the solidified 
magnetite-loaded PHBV nanoparticles were harvested by centrifugation at 11,000 rpm for 30 min and 
washed three times with distilled water and either stored at 4ºC for immediate use, or lyophilized and 
storage at -80ºC for posterior use. The concentration of magnetite added to MgNPs was equivalent to 
that specified by the commercial MRI contrast agent GastroMARK
®
. 
 
 
 
 
 
 
Fig. 1 Schematic representation of the double emulsion method used to formulate MgNPs. A first water-in-oil 
emulsion (w1/o1) is generating by incorporation of magnetite dissolved in water (gray vial) in an amount of PHBV 
dissolved in dichloromethane (blue vial) by sonication until to obtain a homogeneous phase. This first emulsion after 
is added to a larger volume polyvinyl alcohol (PVA) (orange vial) and sonicated to get a second emulsion (w1/o1/w2). 
The PVA is an aqueous solution that provides stabilization to the nanoparticles. Finally, these emulsions are 
arranged in a shaker system during 12 hrs to evaporate the solvent and solidified the nanoparticles, which after are 
washed by centrifugation and either stored at 4ºC for immediate use, or lyophilized and storage at -80ºC. 
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CHARACTERIZATION 
X-ray diffraction (XRD) of magnetite  
Magnetite nanoparticles were identified by comparing the X-ray diffraction (XRD) patterns obtained 
from randomly oriented powder mounts with a Philips X’Pert diffractometer (graphite-monochromated 
Cu-Kα radiation) and ICDD-PDF data.  
Analysis by electronic transmission microscopy (TEM)  
The magnetite particles and MgNPs were characterized by transmission electron microscopy (TEM) 
(Phillips-TECNAI 12 BIOTWIN EM Microscope, FEI Company, Hillsboro, OR). The samples of 
magnetite were prepared by depositing 0.1 mL of the magnetite suspension (1.0 mg/mL) onto a 300-
mesh carbon-coated copper grid. The diameter of magnetite nanoparticles was determined by 
analyzing five images from three independent samples using the Image J software (NIH). In the case of 
MgNP, the samples were prepared by depositing 0.1 mL of the MgNP suspension (1.0 mg/mL) onto a 
300-mesh carbon-coated copper grid, and negatively stained for 5 min at room temperature with 
freshly prepared and sterile-filtered aqueous uranyl acetate solution (2% w/v). The grids were washed 
with distilled water prior to imaging. All samples were analyzed at 80 kV with an acceleration voltage of 
200 kV.  
Size and zeta potential of MgNPs  
The size, in nm, and zeta potential, in mV, of the MgNPs were evaluated using Dynamic light scattering 
(DLS). The samples were suspended in 1 mL of PBS (phosphate buffered saline) at pH 7.4, and 
analyzed at 298 K (room temperature) in a Zetasizer 3000 (Malvern Instruments, UK). The results 
obtained were calculated from three independent experiments.  
Magnetic measurements  
The magnetic properties of the magnetite and MgNPs were compared with those of GastroMARK
®
 
(Ferumoxsil, oral suspension). Magnetic measurements were carried out using a vibrating sample 
magnetometer (VSM), and the hysteresis loop was measured at 300 K as a function of an external 
applied field, Ha.  
Magnetic accumulation of MgNPs in intestinal tissue  
Fluorescent MgNPs were prepared with the same protocol used to formulate the magnetite-loaded 
PHBV nanoparticles by the incorporation of Alexa Fluor
®
 488 dye (Catalogue Number, A32750, 
Molecular Probes-Invitrogen, Carlsbad, CA) in the aqueous phase of the first emulsion. The 
accumulation magnetic nanoparticles were analyzed in segments of the small intestine of rats under 
the presence and absence of an applied magnetic field.  
Six male adult Sprague-Dawley rats (Central Vivarium of the Faculty of Medicine, University of Chile, 
Santiago, Chile) weighing 200-250 g were separated in two groups: experimental (n = 3) and control (n 
= 3). The animals were housed 3 per cage, kept in a room temperature and light-controlled 
environment (12:12 hrs, light: dark cycle with lights on at 7.00 AM) and had ad libitum access to food 
and water. The housing conditions and experimental procedures follow the protocols approved by the 
Bioethics Committee of Universidad Andrés Bello, and in accordance with the "Guide for Care and Use 
of Laboratory Animals" published by the U.S. National Institutes of Health.  
Experimentally, two segments of 3 cm length of the small intestine of each animal were obtained by 
surgical procedures after sacrificing by anaesthetic overdose of isoflurane, and the samples were 
separated in two groups (experimental and control). In the experimental group, a cylindrical 
neodymium magnet (4.540 gauss) of 6 mm x 6 mm was fixed in the middle portion of the small 
intestine using LiquiVet tissue-adhesive (Oasis Medical Mettawa, Illinois, USA), while no magnetic field 
was applied to the control group. The samples were washed three times with 1 mL of phosphate 
buffered saline (PBS), pH 7.4 (0.14 M sodium chloride, 0.003 M potassium chloride, 0.002 M 
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potassium phosphate, 0.01 M sodium phosphate) and then were inoculated with 100 μL of suspension 
of 6 mg/mL of alexa fluor-loaded magnetic nanoparticles (af-MgNPs). Finally, samples were washed 
ten times with 1 mL of PBS (pH 7.4), and the accumulation of fluorescent nanoparticles in the tissue 
was analyzed in the iBox Scientia Small Animal Imaging System (Upland, CA, USA).  
RESULTS AND DISCUSSION  
Superparamagnetic iron oxide nanoparticles  
Iron oxide particles were synthesized using a co-precipitation method, which is a highly reproducible 
technique that generates particles that are almost uniform in size. The XRD results (Figure 2) showed 
a typical magnetite (Fe3O4) pattern with an interplanar spacing (d) of 4.84, 2.97, 2.53, 2.42, 2.10, 1.71, 
1.62, and 1.48 Å. When compared with the reflection ICDD-PDF card # 01-085-1436, these peaks 
confirmed the exclusive presence of magnetite. TEM analysis revealed spherical particles with a 
diameter of 22.3 ± 8.8 nm (Figure 3a). Even considering their small size, these results suggest that the 
magnetite particles show superparamagnetic behaviour.  
 
 
Fig. 2 X-ray Diffraction (XRD) of synthetized magnetite. Numbers indicate the d-values (Å) of interplanar 
spacing. The patterns obtained were compared with the reflection ICDD-PDF card # 01-085-1436, which confirmed 
the sole presence of magnetite. 
Magnetite-loaded PHBV nanoparticles (MgNPs)  
The MgNPs were formulated using a modified double-emulsion evaporation method. Prior, the 
synthetic magnetite particles obtained by co-precipitation were efficiently suspended in water and 
incorporated in the aqueous phase of the first emulsion. The rational design of MgNPs comprised the 
use of PVA as an emulsifier and stabilizing agent. PVA confers remarkably low cytotoxicity and a 
negative zeta potential to nanoparticles (DeMerlis and Schoneker, 2003; Roy et al. 2010; Dong et al. 
2011). Charges on the nanoparticle surface produce repulsive electrostatic forces that prevent 
aggregation and help to stabilize the suspension (Min et al. 2008). In addition, the negative charge of 
the nanoparticles is particularly useful for biomedical applications, because positively charged micro 
and nanoparticles stimulate their uptake by monocytes and macrophages, thereby decreasing their 
bioavailability (Nel et al. 2009). The zeta potential of MgNPs was determined in a Zetasizer 3000 and 
exhibited -10.8 ± 3.5 mV. The negative zeta potential of MgNPs was consistent with other studies that 
used PVA as an emulsifier and stabilizing agent (Liu et al. 2007; Zhao et al. 2007). It was not possible 
to characterize MgNPs by XRD because magnetite content in the sample is below the detection limit of 
this technique (less than 5%). Because the polymer is not crystalline, the signal obtained is part of the 
noise of the measurement.  
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Fig. 3 Transmission electron microscopy (TEM) of magnetite and MgNPs. (a) Magnetite. (b) MgNPs stained 
with uranyl acetate solution, which enhances the electron density of hydrophilic areas. The MgNPs showed a core-
shell structure (polymer-hollow) and a uniform inner magnetite load. 
Size of MgNPs  
The analysis by dynamic light scattering (DLS) of MgNPs showed a size (diameter, nm) of 258.6 ± 35.7 
nm as shown in Figure 4. These results could support to use the MgNPs in medical applications, 
particularly those related to cancer diagnosis and/or treatment, because nanoparticles ranging 10-500 
nm in diameter can extravasate (escape from the blood vessels) into tumour tissues due to passive 
targeting by the enhanced permeation and retention (EPR) phenomenon. EPR is essential for tumour 
growth, as it provides an adequate supply of oxygen and nutrients (Maeda, 2001). On the other hand, 
the size distribution of the MgNPs was uniform, as previously reported by other authors using similar 
procedures to formulate nanoparticles (Yang et al. 2006; Liu, et al. 2007). However, the average 
diameter of MgNPs was smaller than the commercial product based on magnetite covered with silicone 
(GastroMARK
®
) which has about ~400 nm in diameter.  
Fig. 4 Size distribution of MgNPs obtained by dynamic light scattering (DLS). The average diameter of the 
MgNPs was 258.6 ± 35.7 nm. 
Analysis by transmission electron microscopy  
TEM examination of MgNPs revealed spherical nanosized nanoparticles comprising a core-shell 
structure, and three layers with different electron densities. The external layer represented the PHBV 
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polymer and had a thickness of approximately 30 to 40 nm; the layer at the polymer-core interface 
showed a higher concentration of magnetite; and the inner core contained an almost homogeneous 
distribution of magnetite. In addition, the negative staining by uranyl acetate, which increases the 
contrast of hydrophilic structures, exhibited that the interface core-PHBV display the most hydrophilic 
structure inside of MgNPs, being a putative site for load water soluble drugs, and the PHBV polymeric 
layer for hydrophobic drugs (Figure 3b).  
Magnetite inside the MgNPs exhibited a more uniform distribution than previous formulations based on 
the PLGA polymer or those obtained using a similar double emulsion method (Ngaboni Okassa et al. 
2005; Wang et al. 2008). This is important for biomedical applications where the size control is crucial. 
Therefore a more uniform size distribution represents a narrower magnetization distribution and thus a 
reproducible magnetic response.  
Magnetic characterization  
The magnetic characterization of magnetite non-encapsulated (Fe3O4) and MgNPs was carried out in a 
vibrating sample magnetometer (VSM). The magnetic properties of the synthesized magnetite and 
MgNPs were compared with those of GastroMARK
®
. The hysteresis loops (Figure 5) showed a 
saturation of approximately 8 emu/g for magnetite and 6 emu/g for MgNPs. These results were higher 
than those for GastroMARK
®
 (2 emu/g). Magnetite and MgNPs exhibited neither remanence nor 
coercivity, confirming their superparamagnetic behaviour. The differences in saturation values between 
MgNPS and magnetite are due to the difference in concentration of magnetic material present in each 
sample.  
 
Fig. 5 Hysteresis loops of magnetite, MgNPs, and GastroMARK
®
 obtained with a vibrating magnometer 
(VSM) at room temperature as a function of the external field. 
Magnetic accumulation in intestinal tissue  
The tissue-accumulation of alexa fluor-loaded magnetic nanoparticles (af-MgNPs) was assessed in 
segments of the small intestine of rats in the presence and absence of a magnetic field adhered to the 
serous membrane of intestinal tissue. The results showed in Figure 6 exhibits a significant 
accumulation of af-MgNPs in the segments of the small intestine in presence of a magnet fixed in the 
middle portion, which support their use as nanocarrier to site-specific delivery of drug. In addition, the 
biodegradable/biocompatible polymeric structure of MgNPs and their superparamagnetic character 
make them promising candidates for theranostic purposes as MRI contrast agents and for the induction 
of electromagnetic hyperthermia. 
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Fig. 6 Magnetic accumulation of alexa fluor-loaded magnetic nanoparticles (af-MgNPs) in a segment of the 
small intestine with a cylindrical neodymium magnet (M) (4.540 gauss, 6 x 6 mm) and visualized by an 
animal imaging system. Experimental (E) and control (C) groups.  
CONCLUDING REMARKS 
In this study, we report the synthesis and characterization of magnetite and magnetite-loaded PHBV 
nanoparticles (MgNPs) for biomedical applications. The MgNPs showed an average size of ~250 nm, a 
spherical shape with a core-shell structure, and homogenous inner distribution of magnetite. Magnetic 
characterization by VSM shows the superparamagnetic behaviour of magnetite, MgNPs synthetized 
and MRI contrast agent GastroMARK
®
. Such magnetic property makes MgNPs a suitable system as 
MRI contrast agent and even could be used in experimental hyperthermia treatment. Finally, the in vitro 
tissue-retention analysis suggests that MgNPs promise as site-specific nanocarriers of drug. 
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